Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
BIOTISSUE HOLDINGS INC. has 4 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 4 actions are being handled by 4 distinct examiners, ensuring that each matter is reviewed independently by a different individual. The portfolio is spread across 3 distinct art units, indicating some technical concentration within the biotechnology field despite the examiner variety.
ALYSSA G WESTON is the busiest examiner with 1 pending action. Since all 4 distinct examiners have only one action each, the prosecution workload is evenly distributed across the assigned USPTO personnel. The 3 distinct art units for 4 pending actions suggest that while the examiners are different, some of the underlying technologies may be related enough to fall under the same examination groups.
With 4 pending office actions and 4 distinct examiners, the company must manage 4 separate prosecution tracks. The 3 distinct art units provide some level of technical focus, but the lack of examiner overlap means that each case will be subject to a unique set of reviewer preferences. Practitioners should be prepared for 4 different interpretations of the prior art within the Biotechnology & Pharmaceuticals domain.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (67%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PAULUS, ERIN VIRGINIA | 1 | 20.0% | +94.1% |
| MOSS, NATALIE M | 1 | 30.7% | +17.2% |
| BATES, KEENAN ALEXANDER | 1 | 44.9% | +79.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18033470 | METHODS FOR PROCESSING FETAL SUPPORT TISSUE | PAULUS, ERIN VIRGINIA | 27d |
| 17291070 | METHODS OF CELLULAR REPROGRAMMING | BATES, KEENAN ALEXANDER | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18033470 | METHODS FOR PROCESSING FETAL SUPPORT TISSUE | PAULUS, ERIN VIRGINIA | 27d |
| 17914691 | METHODS OF USING UMBILICAL CORD PRODUCTS FOR TREATMENT OF OCULAR SURFACE DISORDERS | MOSS, NATALIE M | — |
| 17291070 | METHODS OF CELLULAR REPROGRAMMING | BATES, KEENAN ALEXANDER | — |
| Art Unit | Apps |
|---|---|
| 1631 | 2 |
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18033470 | METHODS FOR PROCESSING FETAL SUPPORT TISSUE | PAULUS, ERIN VIRGINIA | 1631 | §103 | Final Rejection | 27d | Pending | Apr 24, 2023 |
| 17914691 | METHODS OF USING UMBILICAL CORD PRODUCTS FOR TREATMENT OF OCULAR SURFACE DISORDERS | MOSS, NATALIE M | 1653 | §103 | Non-Final OA | — | Pending | Sep 26, 2022 |
| 17291070 | METHODS OF CELLULAR REPROGRAMMING | BATES, KEENAN ALEXANDER | 1631 | §103§112 | Non-Final OA | — | Pending | May 04, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBIOTISSUE HOLDINGS INC. has 3 pending office actions as of October 2026, spread across 2 art units and 3 examiners.
Erin Virginia Paulus has the most, with 1 of BIOTISSUE HOLDINGS INC.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
